The treatment was approved in October 2021 and is the first FDA-approved therapy to treat macular edema associated with uveitis via injection to the suprachoroidal space, which provides a more ...

Credit: Getty Images. The approval was based on data from the pivotal phase 3 PEACHTREE trial, the phase 3 MAGNOLIA study, and the open-label safety AZALEA trial. The Food and Drug Administration (FDA ...

Xipere approval was based on data from the phase 3 PEACHTREE trial, which included 160 patients with macular edema associated with anterior-, intermediate-, posterior-, or pan-uveitis. Xipere ® ...

Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the Retina Society meeting, Steven Yeh, MD, of Stanley M. Truhlsen Eye ...

(RTTNews) - Bausch + Lomb, the eye health business of Bausch Health Companies Inc. (BHC, BHC.TO), and Clearside Biomedical, Inc. (CLSD) announced Monday the U.S. commercial launch of XIPERE ...

Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, explains the delivery mechanism and benefits of Xipere for macular edema. Steven ...

ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Xipere received a Category 1 CPT code. The new code and ...

ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

ALPHARETTA, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve ...

BEIJING – Eye disease specialist Arctic Vision (Shanghai) Biotechnology Co. Ltd. has in-licensed from Clearside Biomedical Inc., an U.S. ophthalmology biotech, the commercialization and development ...

Clearside Biomedical lost more than half its stock value today after it said it was scrapping clinical development of its lead candidate Xipere (formerly suprachoroidal CLS-TA) for retinal vein ...